Drugs
-
Bupropion hydrochloride (marketed as Wellbutrin, Zyban, and generics) Information
Bupropion hydrochloride is marketed under the following names:
Wellbutrin
Wellbutrin SR
Wellbutrin XL
Zyban
bupropion hydrochloride
Adverse reactions or quality problems experienced with the use of this Product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.
-
Related Information
FDA Update: Budeprion XL 300 mg Not Therapeutically Equivalent to Wellbutrin XL 300 mg
10/3/2012Questions and Answers Regarding Market Withdrawal of Budeprion XL 300 mg Manufactured by Impax and Marketed by Teva
10/3/2012Review of Therapeutic Equivalence Generic Bupropion XL 300 mg and Wellbutrin XL 300 mg Pharmacokinetic Assessment of Two Extended Release Prescription Products (PDF - 144KB)Division of Bioequivalence Review of Pharmacokinetic and Dissolution Data (PDF - 1.7MB)Bioequivalence Evaluation of Innovator and Generic Bupropion XL Products (PDF - 15.3MB)Public Health Advisory: FDA Requires New Boxed Warnings for the Smoking Cessation Drugs Chantix and Zyban
7/1/2009Information for Healthcare Professionals: Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics)
7/1/2009- Podcast: FDA Requires New Boxed Warnings for the Smoking Cessation Drugs Chantix and Zyban
7/7/2009 Antidepressant Use in Children, Adolescents, and Adults
5/2007- Information for Healthcare Professionals: Bupropion hydrochloride (marketed as the antidepressant Wellbutrin)
7/8/2005 Public Health Advisory: Suicidality in Adults Being Treated with Antidepressant Medications
6/30/2005Medication Guide for Antidepressant Drugs (PDF - 28KB)
-
-
Labeling and Regulatory History from Drugs@FDA
-
-
-
